Literature DB >> 33777055

Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results.

Andrea Lombardi1,2, Giorgio Bozzi1, Riccardo Ungaro1, Simone Villa3, Valeria Castelli1, Davide Mangioni1, Antonio Muscatello1, Andrea Gori1,2,3, Alessandra Bandera1,2,3.   

Abstract

Background: BNT162b2 and mRNA-1273 are the two recently approved mRNA-based vaccines against COVID-19 which has shown excellent safety and efficacy. Preliminary data about specific and neutralizing antibodies is available covering the first 100 days after vaccination.
Methods: We reviewed all the publications regarding the immunologic consequences of BNT162b2 and mRNA-1273 vaccination. A summary of specific antibodies concentration and neutralizing antibodies titers elicited by each vaccine is provided.
Results: BNT162b2 and mRNA-1273 displayed a reassuring safety and efficacy profile, with the latter above 94%. They can elicit specific antibodies titers and neutralizing antibodies concentrations that are far superior from those observed among COVID-19 human convalescent serum, across a wide span of age, for at least 100 days after vaccination. Moreover, the vaccine-induced T cellular response is oriented toward a TH1 response and no evidence of vaccine-enhanced disease have been reported. Discussion: BNT162b2 and mRNA-1273 can elicit specific antibodies titers and neutralizing antibodies concentrations above those observed among COVID-19 human convalescent serum in the first 100 days after vaccination. Data about vaccine efficacy in those with previous COVID-19 or immunocompromised is still limited.
Copyright © 2021 Lombardi, Bozzi, Ungaro, Villa, Castelli, Mangioni, Muscatello, Gori and Bandera.

Entities:  

Keywords:  COVID-19; CTL; RNA vaccine; SARS-CoV-2; antibodies; neutralization test

Mesh:

Substances:

Year:  2021        PMID: 33777055      PMCID: PMC7994748          DOI: 10.3389/fimmu.2021.657711

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  26 in total

1.  SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.

Authors:  Nina Le Bert; Anthony T Tan; Kamini Kunasegaran; Christine Y L Tham; Morteza Hafezi; Adeline Chia; Melissa Hui Yen Chng; Meiyin Lin; Nicole Tan; Martin Linster; Wan Ni Chia; Mark I-Cheng Chen; Lin-Fa Wang; Eng Eong Ooi; Shirin Kalimuddin; Paul Anantharajah Tambyah; Jenny Guek-Hong Low; Yee-Joo Tan; Antonio Bertoletti
Journal:  Nature       Date:  2020-07-15       Impact factor: 49.962

Review 2.  mRNA vaccines - a new era in vaccinology.

Authors:  Norbert Pardi; Michael J Hogan; Frederick W Porter; Drew Weissman
Journal:  Nat Rev Drug Discov       Date:  2018-01-12       Impact factor: 84.694

3.  Rapid COVID-19 vaccine development.

Authors:  Barney S Graham
Journal:  Science       Date:  2020-05-08       Impact factor: 47.728

Review 4.  SARS-CoV-2 vaccines in development.

Authors:  Florian Krammer
Journal:  Nature       Date:  2020-09-23       Impact factor: 49.962

5.  Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.

Authors:  Kizzmekia S Corbett; Barbara Flynn; Kathryn E Foulds; Joseph R Francica; Seyhan Boyoglu-Barnum; Anne P Werner; Britta Flach; Sarah O'Connell; Kevin W Bock; Mahnaz Minai; Bianca M Nagata; Hanne Andersen; David R Martinez; Amy T Noe; Naomi Douek; Mitzi M Donaldson; Nadesh N Nji; Gabriela S Alvarado; Darin K Edwards; Dillon R Flebbe; Evan Lamb; Nicole A Doria-Rose; Bob C Lin; Mark K Louder; Sijy O'Dell; Stephen D Schmidt; Emily Phung; Lauren A Chang; Christina Yap; John-Paul M Todd; Laurent Pessaint; Alex Van Ry; Shanai Browne; Jack Greenhouse; Tammy Putman-Taylor; Amanda Strasbaugh; Tracey-Ann Campbell; Anthony Cook; Alan Dodson; Katelyn Steingrebe; Wei Shi; Yi Zhang; Olubukola M Abiona; Lingshu Wang; Amarendra Pegu; Eun Sung Yang; Kwanyee Leung; Tongqing Zhou; I-Ting Teng; Alicia Widge; Ingelise Gordon; Laura Novik; Rebecca A Gillespie; Rebecca J Loomis; Juan I Moliva; Guillaume Stewart-Jones; Sunny Himansu; Wing-Pui Kong; Martha C Nason; Kaitlyn M Morabito; Tracy J Ruckwardt; Julie E Ledgerwood; Martin R Gaudinski; Peter D Kwong; John R Mascola; Andrea Carfi; Mark G Lewis; Ralph S Baric; Adrian McDermott; Ian N Moore; Nancy J Sullivan; Mario Roederer; Robert A Seder; Barney S Graham
Journal:  N Engl J Med       Date:  2020-07-28       Impact factor: 91.245

6.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

Authors:  Lindsey R Baden; Hana M El Sahly; Brandon Essink; Karen Kotloff; Sharon Frey; Rick Novak; David Diemert; Stephen A Spector; Nadine Rouphael; C Buddy Creech; John McGettigan; Shishir Khetan; Nathan Segall; Joel Solis; Adam Brosz; Carlos Fierro; Howard Schwartz; Kathleen Neuzil; Larry Corey; Peter Gilbert; Holly Janes; Dean Follmann; Mary Marovich; John Mascola; Laura Polakowski; Julie Ledgerwood; Barney S Graham; Hamilton Bennett; Rolando Pajon; Conor Knightly; Brett Leav; Weiping Deng; Honghong Zhou; Shu Han; Melanie Ivarsson; Jacqueline Miller; Tal Zaks
Journal:  N Engl J Med       Date:  2020-12-30       Impact factor: 91.245

7.  Correlates of protection against SARS-CoV-2 in rhesus macaques.

Authors:  Katherine McMahan; Jingyou Yu; Noe B Mercado; Carolin Loos; Lisa H Tostanoski; Abishek Chandrashekar; Jinyan Liu; Lauren Peter; Caroline Atyeo; Alex Zhu; Esther A Bondzie; Gabriel Dagotto; Makda S Gebre; Catherine Jacob-Dolan; Zhenfeng Li; Felix Nampanya; Shivani Patel; Laurent Pessaint; Alex Van Ry; Kelvin Blade; Jake Yalley-Ogunro; Mehtap Cabus; Renita Brown; Anthony Cook; Elyse Teow; Hanne Andersen; Mark G Lewis; Douglas A Lauffenburger; Galit Alter; Dan H Barouch
Journal:  Nature       Date:  2020-12-04       Impact factor: 49.962

8.  Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.

Authors:  Mark J Mulligan; Kirsten E Lyke; Nicholas Kitchin; Judith Absalon; Alejandra Gurtman; Stephen Lockhart; Kathleen Neuzil; Vanessa Raabe; Ruth Bailey; Kena A Swanson; Ping Li; Kenneth Koury; Warren Kalina; David Cooper; Camila Fontes-Garfias; Pei-Yong Shi; Özlem Türeci; Kristin R Tompkins; Edward E Walsh; Robert Frenck; Ann R Falsey; Philip R Dormitzer; William C Gruber; Uğur Şahin; Kathrin U Jansen
Journal:  Nature       Date:  2020-08-12       Impact factor: 69.504

9.  Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers.

Authors:  Sheila F Lumley; Denise O'Donnell; Nicole E Stoesser; Philippa C Matthews; Alison Howarth; Stephanie B Hatch; Brian D Marsden; Stuart Cox; Tim James; Fiona Warren; Liam J Peck; Thomas G Ritter; Zoe de Toledo; Laura Warren; David Axten; Richard J Cornall; E Yvonne Jones; David I Stuart; Gavin Screaton; Daniel Ebner; Sarah Hoosdally; Meera Chand; Derrick W Crook; Anne-Marie O'Donnell; Christopher P Conlon; Koen B Pouwels; A Sarah Walker; Tim E A Peto; Susan Hopkins; Timothy M Walker; Katie Jeffery; David W Eyre
Journal:  N Engl J Med       Date:  2020-12-23       Impact factor: 91.245

10.  Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans.

Authors:  Jeffrey Seow; Carl Graham; Blair Merrick; Sam Acors; Suzanne Pickering; Kathryn J A Steel; Oliver Hemmings; Aoife O'Byrne; Neophytos Kouphou; Rui Pedro Galao; Gilberto Betancor; Harry D Wilson; Adrian W Signell; Helena Winstone; Claire Kerridge; Isabella Huettner; Jose M Jimenez-Guardeño; Maria Jose Lista; Nigel Temperton; Luke B Snell; Karen Bisnauthsing; Amelia Moore; Adrian Green; Lauren Martinez; Brielle Stokes; Johanna Honey; Alba Izquierdo-Barras; Gill Arbane; Amita Patel; Mark Kia Ik Tan; Lorcan O'Connell; Geraldine O'Hara; Eithne MacMahon; Sam Douthwaite; Gaia Nebbia; Rahul Batra; Rocio Martinez-Nunez; Manu Shankar-Hari; Jonathan D Edgeworth; Stuart J D Neil; Michael H Malim; Katie J Doores
Journal:  Nat Microbiol       Date:  2020-10-26       Impact factor: 17.745

View more
  18 in total

1.  Changes in the frequency and clinical features of acute rheumatic fever in the COVID-19 era: a retrospective analysis from a single center.

Authors:  Fuat Laloğlu; Naci Ceviz
Journal:  Rev Assoc Med Bras (1992)       Date:  2022-09       Impact factor: 1.712

2.  High Incidence of SARS-CoV-2 Variant of Concern Breakthrough Infections Despite Residual Humoral and Cellular Immunity Induced by BNT162b2 Vaccination in Healthcare Workers: A Long-Term Follow-Up Study in Belgium.

Authors:  Bas Calcoen; Nico Callewaert; Aline Vandenbulcke; Winnie Kerstens; Maya Imbrechts; Thomas Vercruysse; Kai Dallmeier; Johan Van Weyenbergh; Piet Maes; Xavier Bossuyt; Dorinja Zapf; Kersten Dieckmann; Kim Callebaut; Hendrik Jan Thibaut; Karen Vanhoorelbeke; Simon F De Meyer; Wim Maes; Nick Geukens
Journal:  Viruses       Date:  2022-06-09       Impact factor: 5.818

3.  Correlation Analysis of Anti-SARS-CoV-2 RBD IgG and Neutralizing Antibody against SARS-CoV-2 Omicron Variants after Vaccination.

Authors:  Nuchjira Takheaw; Chalerm Liwsrisakun; Warawut Chaiwong; Witida Laopajon; Supansa Pata; Juthamas Inchai; Pilaiporn Duangjit; Chaicharn Pothirat; Chaiwat Bumroongkit; Athavudh Deesomchok; Theerakorn Theerakittikul; Atikun Limsukon; Pattraporn Tajarernmuang; Nutchanok Niyatiwatchanchai; Konlawij Trongtrakul; Watchara Kasinrerk
Journal:  Diagnostics (Basel)       Date:  2022-05-25

4.  Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study.

Authors:  Xavier Sáez-Llorens; Claudio Lanata; Elaine Aranguren; Carlos R Celis; Rubelio Cornejo; Rodrigo DeAntonio; Lucie Ecker; Diegi Garrido; Ana I Gil; Marina Gonzales; Morgan Hess-Holtz; Geert Leroux-Roels; Helga Junker; Sarah-Katharina Kays; Sven D Koch; Sandra Lazzaro; Philipp Mann; Gianluca Quintini; Barkha Srivastava; Dominik Vahrenhorst; Philipp von Eisenhart-Rothe; Olaf-Oliver Wolz; Lidia Oostvogels
Journal:  Vaccine X       Date:  2022-07-01

5.  Seroconversion Following COVID-19 Vaccination in Immune Deficient Patients.

Authors:  Jacqueline Squire; Dr Avni Joshi
Journal:  Ann Allergy Asthma Immunol       Date:  2021-05-19       Impact factor: 6.347

Review 6.  New Generation Vaccines for COVID-19 Based on Peptide, Viral Vector, Artificial Antigen Presenting Cell, DNA or mRNA.

Authors:  Marzieh Rezaei; Mahboobeh Nazari
Journal:  Avicenna J Med Biotechnol       Date:  2022 Jan-Mar

7.  Modelling the concentration of anti-SARS-CoV-2 immunoglobulin G in intravenous immunoglobulin product batches.

Authors:  Sara Stinca; Thomas W Barnes; Peter Vogel; Wilfried Meyers; Johannes Schulte-Pelkum; Daniel Filchtinski; Laura Steller; Thomas Hauser; Sandro Manni; David F Gardiner; Sharon Popik; Nathan J Roth; Patrick Schuetz
Journal:  PLoS One       Date:  2021-11-29       Impact factor: 3.240

8.  COVID‑19 vaccination and IgG and IgA antibody dynamics in healthcare workers.

Authors:  Sabina Zurac; Luciana Nichita; Bogdan Mateescu; Cristian Mogodici; Alexandra Bastian; Cristiana Popp; Mirela Cioplea; Claudiu Socoliu; Carolina Constantin; Monica Neagu
Journal:  Mol Med Rep       Date:  2021-06-16       Impact factor: 2.952

Review 9.  From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape.

Authors:  Chiranjib Chakraborty; Ashish Ranjan Sharma; Manojit Bhattacharya; Sang-Soo Lee
Journal:  Front Immunol       Date:  2021-07-07       Impact factor: 7.561

Review 10.  The Immune Response to SARS-CoV-2 and Variants of Concern.

Authors:  Elham Torbati; Kurt L Krause; James E Ussher
Journal:  Viruses       Date:  2021-09-23       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.